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Available online 2 July 2016Background: Antithrombin III (ATIII) is a protein that inhibits abnormal blood clots (or coagulation) by breaking
down thrombin and factor Xa. ATIII helps to keep a healthy balance between hemorrhage and coagulation.
The present work demonstrated the production, puriﬁcation and characterization of recombinant human
antithrombin (rhAT) from yeast Saccharomyces cerevisiae BY4741 was demonstrated. After expression of rhAT
by S. cerevisiae, the biomass and rhAT concentration were analyzed through fed-batch fermentation process.
Results: In fed-batch fermentation, the biomass (maximum cell dry weight of 11.2 g/L) and rhAT concentration
(312 mg/L) of the expressed rhAT were achieved at 84 h of cultivation time. The maximum cell lysis efﬁciency
(99.89%) was found at 8 s sonication pulse and 7 mL lysis buffer volume. The rhAT protein solution was
concentrated and partially puriﬁed using cross-ﬂow ﬁltration with the recovery yield and purity of 95
and 94%, respectively. The concentrated solution was further puriﬁed by the single step ion exchange
chromatography with the recovery yield and purity of 55 and ≥98%, respectively. The puriﬁed rhAT was
characterized by various analytical techniques, such as RP-HPLC, FT-IR, CD, SDS-PAGE, western blotting, and
Liquid chromatography mass spectrometry (LC–MS) analysis. The biological activity of rhAT was analyzed as
heparin cofactor to meet the therapeutic grade applications.
Conclusions: The simple, cost-effective and economically viable nature of the process used in the present study for
the production of rhAT will be highly beneﬁcial for the healthcare sector. This may also be used to produce other
value-added therapeutic recombinant proteins expressed in S. cerevisiae, with greater effectiveness and ease.
©2016 PontiﬁciaUniversidadCatólica deValparaíso. Production andhostingbyElsevier B.V. All rights reserved. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Antithrombin (AT) plays a central role in the regulation of blood
coagulation and is the major physiological serine proteinase inhibitor
that inactivates abundant proteinases in the case of blood coagulation
cascade, mainly thrombin and factor Xa [1,2]. AT is a single-chain
glycoprotein (432 amino acids, MW 58 kDa) with three disulﬁde
bridges and four carbohydrate side chains linked at four asparagine
residue sites asparagine residue sites (96, 135, 155, and 192), which
account for 15% of the total mass [3,4]. It is usually present in human
plasma at a level of 150 mg/L [5]. It also inactivates target proteinase
by forming a 1:1 stoichiometric stable covalent complex with the
reactive center arginine-393 of AT and reactive site serine residue
of the proteinase [6]. The inhibitory activity of AT for thrombin isidad Católica de Valparaíso.
araíso. Production and hosting by Elsaccelerated 1000 fold with the addition of heparin [7]. AT is also
used in the therapeutic treatment of acute thrombotic episodes
and prophylaxis during surgery and pregnancy in patients with AT
shortage [8]. In humans, AT is produced by fractionation of plasma
acquired from the blood donors [9]. Nevertheless, unreliable blood
source causes the potential risk of contamination of the product by
blood-borne pathogens. The production of AT by rDNA technology
would address the concerns of contamination with blood-derived
pathogens [10]. Hence, the industrial-scale production of recombinant
human antithrombin (rhAT) is necessary.
Saccharomyces cerevisiae (yeast) has been extensively used as a
capable host for the production of recombinant proteins. Yeast is
usually preferred as a host over Escherichia coli because it is a eukaryote
and is capable of carrying out post-translational modiﬁcations in order
to achieve biological activity and secondary structure [11,12]. From a
practical biotechnological point of view, S. cerevisiae has a long history
of utilization in large-scale conventional industrial processes, and unlike
E. coli, it lacks measurable endotoxins. Hence, it is regarded as safe
(GRAS) organism for the production of industrial products [13].evier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
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of recombinant proteins from yeast. Batch and fed-batch fermentation
processes are the state-of-the-art bioprocesses used for the production
of industrial products. A fed-batch system enables us to control
the addition of substrate for cell growth and product formation.
This type of fermentation mode increases the cell density and extends
the growth phase of cells compared to the batch fermentation process.
In the fed-batch fermentation, the heterologous porcine insulin
precursor concentration has been reported to reach ﬁve times the
level obtained in the shake ﬂask fermentation process [14].
In the present work, a study has been conducted on batch and
fed-batch fermentation processes to analyze biomass and yield of
rhAT using S. cerevisiae BY4741.
2. Materials and methods
2.1. Production of rhAT in a bioreactor
The recombinant S. cerevisiae BY4741 was cultivated in two modes
of fermentation processes, i.e., batch and fed-batch fermentation, in
a 5 L bioreactor (Minifors, Infors HT, Switzerland) with a working
volume of 3 L. The S. cerevisiae minimal media consisted of 0.67%
yeast nitrogen base (YNB) without uracil (HiMedia), 0.192% drop out
powder (complete supplement mixture: aspartic acid, histidine,
isoleucine, methionine, phenylalanine, proline, serine, tyrosine, and
valine), and 2% carbon source (dextrose or rafﬁnose). The bioreactor
was inoculated with 500 mL of a 30 h pre-culture. Batch fermentation
was started for initial cell growth. After depletion of the initial carbon
source in the batch medium, the feeding was carried out to allow
the cell mass concentration to increase exponentially. After a certain
time (24 h), the fed-batch process was initiated by the addition of
feed consisting of 20% galactose and 10% rafﬁnose at regular time
intervals (10 mL/2 h). The saturated sterile air inside the reactor
was maintained with a condenser, and the pH was analyzed with
a Mettler Toledo (Bedford, MA, USA) glass electrode, which was
maintained at 7.1 ± 0.2 by the addition of 5 N sodium hydroxide
and 3 N phosphoric acid solutions. The dissolved oxygen (DO) was
measured by a Hamilton sensor (Bonaduz AG, GR, Switzerland).
Aeration was provided using a sterile ﬁlter air (0.2 μ), which was
operated at 2.0 vvm, and the agitation was maintained at 250 rpm.
2.2. Cell disruption
The fermented broth was harvested, and the pellet was collected
by centrifugation (Sorvall ST 16 R, Thermo scientiﬁc, USA) at 4°C,
40,000 × g for 15 min. The weight of the pellet was calculated as dry
cell weight (DCW, g/L). The cells were washed with wash buffer
containing 0.05 M ethylenediaminetetraacetic acid (EDTA) (pH 8.0)
and 0.01 M Tris–HCl (pH 7.6). The cells were then lysed by sonication
(20 kHz, for 2–4 time intervals) and frequent homogenization using
lysis buffer containing 0.01 M Tris–HCl (pH 7.6), 1% dimethylsulfoxide
(DMSO), 50 mM NaCl,1 mM EDTA, 0.5% sucrose, and 1 mM
phenylmethylsulfonyl ﬂuoride (PMSF). A very low concentration of
NaCl was used in the lysis buffer since the puriﬁcation process
involved ion exchange chromatography (IEC). The cell lysis procedure
was optimized by employing various sonication pulses and lysis
solution volumes at constant pellet weight of 1 g.
2.3. Analysis of biomass and rhAT concentration during fermentation
The post-induced culture samples (5 mL) were taken at 12 h
intervals for 84 h, and the total cell concentration was determined
by measuring the optical density at 600 nm (OD600) using a UV–Vis
spectrophotometer (Halo DB-20, Dynamica, Australia). The samples
were considered to be diluted if the absorbance was above 0.5. Thecells were collected by centrifugation at 35,000 × g for 10 min, the
supernatant was discarded, and the DCWwas calculated in triplicates.
The concentration of rhAT in the cell lysate solution during fed-batch
fermentation was estimated by reverse phase liquid chromatography
(RP-HPLC) (Shimadzu, Japan) [15]. The concentration of the rhAT was
determined using the rhAT reference standard curve.
2.4. Concentration and partial puriﬁcation by cross-ﬂow ﬁltration system
The protein solution (lysate) was concentrated and clariﬁed using
cross ﬂow-ﬁltration (CFF) system (Quix stand, GE Healthcare Life
sciences, Sweden) through a constant volume of 500 mL. The protein
solution was concentrated using a 30 kDa hollow ﬁber molecular
weight cut-off (MWCO) cartridge (GE Healthcare Bioscience Corp,
USA) with nominal ﬂow path length of 30 cm and a cross-sectional area
of 650 cm2. The protein under CFF is mainly affected by temperature and
transmembrane pressure. Hence, the ﬁltration efﬁciency of rhAT protein
solution was optimized by adopting various ranges of temperature
(18, 22 and 26°C) and transmembrane pressure (12, 16 and 20 psi) [16].
2.5. Puriﬁcation strategies of rhAT
The impure mixture of rhAT is subjected to the IEC step. The
fast protein liquid chromatography system (FPLC), AKTA Prime plus
(GE Healthcare Life sciences, Uppsala, Sweden) was used for the
puriﬁcation of rhAT from the cross ﬂow ﬁltered sample. The size
exclusion chromatography (SEC) (Sephadex G-200) followed by IEC
(SP-Sepharose FF) was performed with Bioprocess glass column (BPG)
XK16/20 and packed with 30 mL of the matrix. The column ﬂow rate
and temperature were maintained at 2 mL/min and 20°C, respectively,
throughout the process. The sodium phosphate buffer (25 mM) at
pH 5.4 was used to equilibrate the stationary phase, and the protein
sample was directly loaded onto the column with the same ﬂow rate.
The elution buffer with 25 mM sodium phosphate, pH 5.4 and 0.5 M
NaCl was used to elute rhAT from the column.
2.6. RP-HPLC analysis
RP-HPLC was performed to analyze the qualitative properties of
rhAT. An HPLC system (Shimadzu, Kyoto, Japan) was ﬁtted with LC
Prominence SPD 20A UV–Visible detector and LC 20 AT binary pumps.
The analysis of rhAT was carried out at the following conditions: ﬂow
rate 1.0 mL/min, wavelength 280 nm, pressure 80 Kgf and controlled
temperature 40°C. The C18 5 μ column (250 × 4.6 mm) (Phenomenex,
USA) was used for rhAT analysis. The mobile phase A consisted of
water: acetonitrile (87.5:12.5 v/v) with 0.1% triﬂuoroacetic acid (TFA),
and the mobile phase B consisted of water: acetonitrile (30:70 v/v)
with 0.08% TFA as an ion pairing agent. The rhAT was eluted using
linear gradient mode with 5% B to 90% B in 20 min and 90% B to 5% B
in 40 min. The injection volume was 20 μL for all the runs, and rhAT
(National Institute for Biological Standards and Control-NIBSC, UK)
was used as a reference standard. All the chromatograms were
stabilized with the major peak, and a chromatogram analysis was
executed through the LC Solution software.
2.7. Secondary structure analysis
The secondary structure of rhAT was characterized by circular
dichroism (CD) and Fourier transform-infrared (FT-IR) spectroscopy.
The CD spectra of puriﬁed rhAT were evaluated using the AVIV
420SF spectropolarimeter (Lakewood, NJ, USA) that was ﬁxed to a
thermostated cell holder and a thermostatic water bath with a
20 nm/min scan speed. The cylindrical cells of high optical quality
(Optical Cell, Woodbine, MD) with a path length of 2 cm were used
to record the spectra and reported the average of ﬁve consecutive
scans. All the experiments were carried out at 24°C. The rhAT spectra
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length quartz cell with a sensitivity of 1 mdeg per cm.
The puriﬁed rhAT secondary structure was also assessed by
FT-IR spectroscopy. FT-IR, Spectrum Two™ (Perkin Elmer, USA) with
Lithium tantalite (LiTa03) infrared detector was used to measure the
rhAT samples. Hygroscopic calcium ﬂuoride (CaF2) glass windows
with 4 μ path length spacer were used to analyze the rhAT samples.
The spectra were achieved from the scan range of 4000 to 450 cm-1
in transmission mode with 32 cm-1 resolution. The best spectra were
acquired by performing 100 scans with a scan speed of 2 cm-1. All
the spectra were smoothed and deconvoluted using Spectrum 10™
software.
2.8. SDS-PAGE and western blot analysis
The purity of rhAT was analyzed by SDS-PAGE and western blotting
analysis. A 12% acrylamide SDS gel was achieved using theMini protean
II system (Bio-Rad Inc., CA, USA). Due to thehighmolecularweight of AT
(58 kDa), the gel was run at a stable 50 V for 4 h to get the clear
separation of bands with a high resolution. After the separation of the
bands, the gel was stained with comassie brilliant blue (CBB) R-250
overnight. After gel electrophoresis, the rhAT protein was moved onto
polyvinylidene diﬂuoride (PVDF) membrane at an invariable voltage
of 50 V for 1 h. The membrane was incubated with blocking buffer
containing 5% skim milk powder and phosphate buffer saline (PBS) for
1 h at room temperature. It was then incubated with the polyclonal
antibody (1:1000) generated from the rabbits for 80 min at 28°C.
The membrane was washed with PBS containing 0.1% Tween 20 and
incubated with horseradish peroxidase (HRPO)-conjugated goat IgG
antibody (Bio-Rad Inc., USA) for 40 min at 28°C. The membrane was
again washed with buffer containing 10 mM Tris (pH 8.0) and 0.5 M
sodium chloride and subsequently incubated with a chromogenic
substrate solution (Thermo Fisher Scientiﬁc, USA).
2.9. Liquid chromatography–mass spectrometry (LC–MS) analysis
Prior to the injection of the sample, the puriﬁed rhAT was diluted
ﬁve-fold with formic acid (0.1%) in water. All the experiments wereFig. 1. Fed-batch fermentation process variables of rhAT from Saccharomyces cerevisiae BY4741.
ended at 84 h. The addition of limiting substrate was started at 6.8 g/L dry cell weight, and the
84 h. The process variables such as rpm and rhAT concentration values were multiplied with 1carried out using an Agilent 1290 UHPLC system that is equipped
with a quaternary pump, vacuum degasser, thermostated well-plate
auto sampler, column oven, and C18 column (Waters, Milford, USA)
joined to an Agilent 6520 QTOF LC/MS mass spectrometer with a
binary-nebulizer. Mobile phase A (0.1% aqueous formic acid) and
mobile phase B (acetonitrile with 0.1% formic acid) were used as
solvents, and 5% B was used during initial conditions at constant
column temperature and ﬂow rate. The optimal ﬂow rate and
temperature were estimated experimentally to be 0.5 mL/min and
50°C, respectively. The gradient program was used as follows:
0–1 min 5% B, 1–6 min 80% B, 6–8 min 95% B, and 8–10 min 5%
B. The mass spectra of rhAT were analyzed with the following QTOF/
source parameters: Nebulizer: 25 psig; Drying Gas: 10 L/min at 300°C;
Sheath gas: 10 L/min at 400°C; VCap: 3000 V; Fragmentor: 100 V; MS
Scan: 100–3200 m/z at 2 spectra/s (Intact Mass); Skimmer: 60 V OCT
1RF; and Vpp: 750 V.
2.10. Biological activity of rhAT
The biological potency of the puriﬁed rhAT was estimated as a
heparin cofactor (HC) activity with a commercially available kit, which
utilizes the thrombin speciﬁc-chromogenic substrate S-2238 (Testzym
antithrombin III 2 assay kit; Daiichi Pure Chemical, Tokyo) [10].
2.11. Statistical analysis
Statistical analysis was conducted using Graph pad In Stat 3.0.
The experiments for protein recovery, purity and bioactivity were
conducted in triplicates of experimentation, and the mean values with
standard deviations (SD) were also recorded.
3. Results and discussion
3.1. Production of rhAT in the bioreactor
When a high cell density is the primary concern, the fed-batch
cultivation is more useful for the biomass and product formation
because the protein expression is in proportion to the cell densityInitially, the processwas operated in batchmode up to 24 h, and the fed-batch processwas
maximum biomass yield (11.2 g/L) and rhAT concentration (312 mg/L) were observed at
0 according to their relevant axis values.
Table 1
Effect of sonication pulses and lysis buffer volumes on cell lysis. The resulting analysis
represents mean values with SD of three repeated experiments.
Parameter Cell lysis efﬁciencya (%)
Sonication pulse (s) 2 98.94 ± 0.02
4 99.20 ± 0.03
6 99.34 ± 0.02
8 99.57 ± 0.04
10 99.52 ± 0.02
Lysis buffer volume (mL) 3 99.68 ± 0.03
5 99.76 ± 0.02
7 99.89 ± 0.02
10 98.59 ± 0.03
a The cell lysate solution was serially diluted with 0.85 M NaCl solution and separately
spread on the YNB-agar plates with ampicillin.
Fig. 2.Native PAGEanalysis of rhAT lysate sampleswith 5 and 10mL of lysis buffer. Lanes 1
and 2 show the rhAT test samples. Lanes 3 and 4 show control AT samples. Similar
antithrombin (58 kDa) bands were observed with respect to different volumes of lysis
buffer volumes (5 and 10 mL) and the molecular weight of both puriﬁed and control
antithrombin (58 kDa) was compared with molecular weight marker (lane M).
Table 3
Effect of temperature and transmembranepressure on rhATﬁltration efﬁciency. The result
84 M.R. Mallu et al. / Electronic Journal of Biotechnology 22 (2016) 81–89[17,18,19]. The rhAT was produced by S. cerevisiae using the batch
and the fed-batch fermentation process. The fed-batch fermentation
proﬁle of rhAT production is illustrated in Fig. 1. It can be seen that
the maximum CDW and rhAT concentration were achieved (11.2 and
312 mg/L, respectively) at 84 h of fermentation process. The overall
productivity of rhAT was signiﬁcantly superior to that of the
previously reported research [20]. The increase in the overall
productivity could be due to the moderate speciﬁc growth rate by the
addition of feed at controlled conditions during fed-batch cultivation.
Initially, the oxygen uptake rate (OUR) was found to be 100% air
saturation that showed a gradual decrease in the dissolved oxygen
concentration (pO2). It was observed that the dissolved oxygen
concentration (40%) at 36 h indicated the presence of exponential
phase cells with a high speciﬁc growth rate. The increase in pO2 was
observed progressively, which indicated that the cells reached a
stationary or decline phase. During fermentation, the pO2 was
maintained at 40% and above to reduce the aggregation of toxic
compounds within the cells. The presented fed-batch process was
conﬁrmed to be a suitable mode of fermentation for the large-scale
production of rhAT.
3.2. Cell lysis analysis
After production, the cellsweredisrupted by frequent homogenization
and sonication processes. To achieve maximum rhAT recovery, the
lysis protocol was optimized by employing various strategies, such as
i) different sonication pulses (2, 4, 6, 8 and 10 s) and ii) different buffer
volumes (3, 5, 7 and 10 mL). The cell lysate solution was serially diluted
with 0.85 M NaCl solution and separately spread on the YNB-agar plates
with ampicillin. The cell lysis efﬁciency was analyzed based on the cell
counting. Table 1 describes the cell lysis efﬁciency with adopted
conditions. It can be observed that the maximum cell lysis efﬁciency
(99.57%) was achieved with 8 s sonication pulse, whereas the lowest
efﬁciency (98.94%) was observed with 2 s sonication pulse.
On the other hand, the highest cell lysis efﬁciency (99.89%) was
achieved with the buffer volume of 7 mL, and the lowest efﬁciency
(99.68%) was observed with 3 mL of buffer volume (Table 1). From
these results, it was clearly observed that buffer volumes should not
be too low or too high, and it must be optimum to achieve maximum
cell lysis efﬁciency.Table 2
The effect of lysis buffer volumes on puriﬁed and control antithrombin with respect to 5
and 10 mL lysis buffer volumes. Similar proﬁle of both puriﬁed and control antithrombin
activity was observed with 5 and 10 mL lysis buffer volumes. The resulting analysis
represents mean values with SD of three repeated experiments.
Lysis buffer volume (mL) with ﬁxed
concentration of AT (0.35 mg/mL)
Puriﬁed rhAT activity
as HC activity (IU/L)
Control AT activity
as HC activity (IU/L)
5 365.7 ± 0.1 366.7 ± 0.1
10 365.3 ± 0.1 366.2 ± 0.1However, to know the effect of lysis buffer volume on rhAT activity,
the cell lysate samples with 5 and 10 mL lysis buffer were subjected
to centrifugation and followed by puriﬁcation (CFF and SEC with
Sephadex G-200). After puriﬁcation, rhAT activity was analyzed as HC
activity through chromogenic assay (TESTZYM ATIII 2 kit; Daiichi
Pure Chemical, Tokyo) with the ﬁxed concentration of puriﬁed rhAT
(0.35 mg/mL). On the other hand, the effect of lysis buffer volume
(5 and 10 mL) was also analyzed on control AT activity with the ﬁxed
concentration of control AT (0.35 mg/mL). From the experimental
results (Table 2), it can be observed that no much variation in the
activity of both puriﬁed and control AT with respect to two different
volumes of lysis buffer (5 and 10 mL). The native PAGE gel (Fig. 2)
was also performed to check the both puriﬁed and control AT activity.
From the experimental observations, it has clearly observed that cell
lysis efﬁciency was affected by variation in lysis buffer volume but not
AT activity and its stability.
3.3. Concentration and partial puriﬁcation
CFF is an efﬁcient process of concentration and partial puriﬁcation of
protein solutions without any loss of proteins and their activity. The
primary concentration and puriﬁcation of recombinant protein are
essential to prepare a clariﬁed feed stream for the ﬁnal puriﬁcation
step [21]. Various recombinant proteins such as recombinant human
granulocyte colony stimulating factor (rhG-CSF) and monoclonal
antibodies have been successfully concentrated using the CFF system
with N95% purity [16,22]. In the present work, an investigation has
been conducted to analyze the effect of temperature (18, 22 and 26°C)analysis was performed in triplicates with mean values of SD.
Physical
parameter
RPM Vo
(mL)
Vp
(mL)
Vr
(mL)
Cf T
(min)
Yield
(%)
Purity
(%)
Temperature
(°C)
18 350 500 410 90 5.55 91 80 ± 1.2 91
22 350 500 454 46 10.86 74 92 ± 1.6 96
26 350 500 421 79 6.32 82 74 ± 1.4 93
Transmembrane
pressure (Psi)
12 350 300 218 82 3.65 65 75 ± 1.5 90
16 350 300 256 44 6.81 48 95 ± 1.3 94
20 350 300 230 70 4.28 57 81 ± 1.2 88
Vo = initial volume; Vp = permeate volume; Vr = retantate volume; Cf = concentration
factor is the ratio of the feed volume to the ﬁnal volume; T = total time (min).
Fig. 3. RP-HPLC proﬁles of cell lysate before and after cross ﬂow ﬁltration. The maximum purity of rhAT (≥94%) was achieved with temperature (22°C) and transmembrane pressure
(16 psi).
Fig. 4. FPLC chromatogram of rhAT eluted through the IEC with SP-Sepharose FF resin. Monomer peak (indicated with *) of rhAT with a good resolution was separated with maximum
recovery yield and purity of 55 and ≥98%, respectively.
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Fig. 5. RP-HPLC analysis of puriﬁed rhAT eluted through a phenomenex C-18 column (250 × 4.6 mm) column. The peaks were auto scaled according to the largest intensity peak. The
maximum purity of the rhAT (≥98%) was observed with retention time 22.756 min.
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and concentration of rhAT protein solution using CFF. Table 3 shows
the ﬁltration efﬁcacy of rhAT solution. The maximum yield (92%) of
rhAT was observed at 22°C with 96% purity and 10.86 concentration
factor. On the other hand, it can be seen that the 16 psi
transmembrane pressure was suitable for the ﬁltration of rhAT with
the yield, purity and concentration factor of 95%, 94% and 6.81,
respectively (Table 3). However, the cell lysate consisted of a mixture
of various proteins, proteins below 30 kDa, cell contaminants like
nucleic acids, DNA, lipopolysaccharides and other cellular components
that moved freely across the permeable membrane. Fig. 3 shows the
RP-HPLC proﬁles of rhAT before and after CFF. It can be seen that
before CFF, the contaminant's population was assimilated with rhAT
protein. After CFF, the generation of concentrated and partially
puriﬁed protein was eluted from the column, and the obtained HPLC
chromatogram indicated a single major peak with fewer impurities.Fig. 6. Secondary structure analysis of rhAT by CD spectroscopy. The CD spectra of both the stan
random coil form (6%) of polypeptide chain components.3.4. Puriﬁcation of rhAT
The objective of a puriﬁcation process is not only the removal of
unnecessary contaminants but also the increase in the concentration
of the target protein and its transfer to an environment, where it
remains stable and ready for the intended application. However, if the
protein is intended towards therapeutic use, it must be extremely
pure. The puriﬁcation must be done in minimum steps to get an
inexpensive drug with a higher degree of purity [23]. Even though, the
heparin afﬁnity columns are available in the market, simple and
cost-effective size exclusion and ion exchange resins were used from
the economic perspective. This can be achieved by choosing the right
combination of puriﬁcation technique. In the present study, the
concentrated and partially puriﬁed rhAT solution was subjected to SEC
followed by IEC. Fig. 4 shows the FPLC chromatogram of rhAT protein
eluted from the SP-sepharose FF ion exchange column. From thedard and puriﬁed rhATwere shown asα-helix (32%), β-sheet (16%), beta turns (10%), and
Fig. 8. SDS-PAGE analysis of puriﬁed rhAT. Lane M protein molecular weight marker, lane
1 rhAT reference standard and, lane 2 puriﬁed rhAT.
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separated from its dimer. AT was puriﬁed with SEC followed by IEC
and conformed to be the monomeric form of rhAT. The same was
revealed and conﬁrmed by RP-HPLC analysis, which is considered to
be sensitive than the PAGE analysis. The monomer peak fraction was
collected at a volume of 10 mL with a concentration of 0.5 mg/mL. The
maximum recovery yield and purity achieved with this step were 55
and ≥98%, respectively. In the present study, signiﬁcant recovery yield
and purity proﬁles of rhAT were achieved with IEC followed by SEC
resins similar to that of heparin afﬁnity columns.
3.5. Characterization of rhAT
The therapeutic molecules produced by r-DNA technology are
extremely complex as compared to the chemically synthesized active
ingredients. The recombinant-based therapeutic proteins show a
higher structural heterogeneity and are subject to a range of
enzymatic or chemical alterations. This protein heterogeneity results
from the sequence variations generated from the proteolysis or
transcriptional/translational errors from post-translational
modiﬁcations, and from the degradation of products, which are
formed through processing and ﬁnal product storage. For that reason,
the characterization and responsive analytical techniques are
compulsory to assure the safety, quality and efﬁcacy of the therapeutic
protein products [24]. In the present study, the puriﬁed rhAT was
characterized using various analytical techniques.
The purity of the rhAT was analyzed by RP-HPLC. Fig. 5 shows
the RP-HPLC chromatogram of rhAT eluted from the IEC. A single
symmetrical peak was obtained, indicating that it contains a
homogeneous population of rhAT conformer with N98% purity, and it
was correlated with the reference to standard rhAT.
The secondary structure of the rhAT was analyzed by the CD and
FT-IR spectroscopy. Fig. 6 shows the structural assessment of rhAT.
The presence of α-helix (32%), β-sheet (16%), β-turns (10%), and
random coil form (6%) of polypeptide chain components with the restFig. 7. FT-IR absorbance spectra of the puriﬁed and reference standard rhAT. Spectra shows
secondary structural components of amide I region consists of α-helix (1663 ± 2 cm-1) and β-of the molecule were found to be in unordered form conﬁrming its
secondary structure, which is in conformity to earlier research [25].
The secondary structure of rhAT was also scrutinized by FT-IR
spectroscopy. The second derivative structure of rhAT was correlated
with reference standard rhAT. Fig. 7 shows the second derivative of
rhAT curve-ﬁtting IR spectra that were compared with a reference
standard (NIBSC, UK). The major spectral variations were viewed
in amide I and amide II due to the possibility of C_O stretching
vibrations (1632 ± 2 cm-1) and N\\H deformation or bending
(1620 ± 2 cm-1) of amides attached with both the puriﬁed and
standard rhAT proteins, respectively. The major spectral vibrationsthe amide I and II bands, which are the backbone of the protein polypeptide chain. The
sheet (1669 ± 2 cm-1).
Fig. 9.Western blot analysis of the puriﬁed rhAT with a reference standard. Lane 1 shows
the puriﬁed rhAT. Lane 2 shows standard rhAT. Western blot analysis of rhAT was
performed using polyclonal antibody generated from the rabbits and horseradish
peroxidase (HRPO)-conjugated goat anti rabbit IgG antibody.
Fig. 11. Biological potency of rhAT by Testzym antithrombin III 2 assay kit (Daiichi
Pure Chemical, Tokyo). A comparison proﬁle of puriﬁed and reference standard of
rhAT activity against various rhAT concentrations were presented. Biological activity
proﬁles of both puriﬁed and reference standard showed signiﬁcant correlation. All the
experiments were performed in triplicates with mean ± standard deviation (P b 0.005).
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analogous nature towards each other along with similar absorption
bands. It was also observed that, in both proteins, the amide I region
represented the secondary structure study by showing the structural
constituents such as α-helix (1663 ± 2 cm-1) and β-sheet (1669 ±
2 cm-1). The above studies are a good evidence for the secondary
structure analysis of the rhAT as contrasted with the reference
standard with 98% correlation.
The puriﬁed rhAT protein was also analyzed by SDS–PAGE and
western blotting. Fig. 8 shows SDS-PAGE analysis of rhAT. A single
target rhAT band conﬁrmed the similarity between molecular mass
(58 kDa) and the pattern exhibited with the standard (NIBSC, UK).
After SDS-PAGE analysis, the gel was transferred to PVDF membrane by
the electro blotting method. The transformation was immunodetected
with rhAT antibodies (Invitrogen Antibodies Fisher Scientiﬁc), and a
single band indicated the presence of rhAT, which was similar toFig. 10. LC–MS analysis of rhAT. Molecular mass of rhAT (57,995.36 Da) was matched withthe reference standard (Fig. 9). Fig. 10 shows LC–MS analysis of rhAT.
The molecular mass of the rhAT was estimated to be 57,995 Da, which
was close to the theoretical mass of 58 kDa.
The puriﬁed rhAT was diluted with 100 mM 2-amino-
2-hydroxymethyl-1, 3-propanediol containing methylamine
hydrochloride with pH 7.5 to make various concentrations of rhAT
(0.1, 0.2, 0.3, 0.4 and 0.5 mg/mL). The rhAT samples with different
concentrations were added to the mixture of thrombin and heparin
(Testzym antithrombin III 2 assay kit; Daiichi Pure Chemical, Tokyo)
before the commencement of the reaction by adding chromogenic
S-2238 (1.43 g/L) substrate. After 5 min, the reaction was terminated
by adding the citric acid solution. The reaction optical density at
405 nm was estimated by spectrophotometry. Fig. 11 shows the
rhAT activity against various concentrations. From the results, it
can be observed that an increase in the biological activity of rhAT
as heparin cofactor activity was observed with increased rhAT
concentration. The results were in accordance with the reference
standard.
4. Concluding remarks
The fed-batch fermentation strategy described in the present
study is trouble-free, highly successful, and reproducible. The CDW
(g/L) and rhAT concentration were analyzed during the fed-batch
fermentation process that exhibited maximum value of 11.2 g/L
and 312 mg/L, respectively. The operation of fed-batch fermentation
at a controlled speciﬁc growth rate of S. cerevisiae through galactose
and rafﬁnose feeding extended the duration of the batch time andthe antithrombin molecular weight, which is conﬁrmed by the Bioconﬁrm software.
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pulses and 7 mL buffer volume of cell lysis protocol, the maximum
cell lysis efﬁciency was found to be 99.89%. The lysate protein solution
was concentrated and partially puriﬁed by CFF with the recovery
yield and purity of 95 and 94%, respectively. Subsequently, it was
ﬁnally puriﬁed by IEC method with the recovery yield and purity of
55 and ≥98%, respectively. The structural components of the amide I
vibration, assessed by CD and FT-IR spectroscopy, revealed the alpha
and beta helix structures that presented strong evidence for its
secondary structural conﬁrmation of rhAT. The puriﬁed rhAT
underwent molecular mass (57,995 Da) analysis by LC/MS analysis.
Finally, an increase in the biological activity of rhAT was observed
with increased rhAT concentration and which is very close to the
reference standard.
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